6 results about "Lipofuscin" patented technology

Based on co-drugs representing two different chemical entities and the co- and sequential administration of the two chemical entities, novel therapies for macular degeneration and TTR amyloidosis are provided. The first component (“selective TTR ligand”) is a chemical entity that binds to TTR in the RBP4 (retinol-binding protein 4)-TTR (transthyretin) complex, which participates in the delivery of retinol to the retina. This component reduces retinol transport from circulation to the retina and provides stabilization of the TTR tetramer. The second component (“C20-D3-visual chromophore-generating compound”) is a C20-D3 modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore, which is presented in the retina as C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at C20 reduces the formation of lipofuscin biretinol, but other functions (such as providing a precursor for the synthesis of the visual chromophore 11-cis-retinaldehyde in vivo) are not reduced.

The present invention provides a basis for using soluble fiber, particularly compositions comprising Agave fructans, to prevent or treat the accumulation of lipids, particularly ceramides in the liver and brain and lipofuscin in the liver, improving the overall integrity of both organs, with treatment being feasible to prevent fatty liver disease and also prevent Alzheimer's disease (AD). In the present invention, we analyze alterations in lipid metabolism in the liver and ceramide production in the brain of transgenic mice (APP / PS1, TG) for AD. Our results indicate that microvesicular lipid accumulation within hepatocytes is increased in TG mice compared to the control group. Furthermore, in the brains of TG mice, a greater accumulation of ceramides is observed in the somatosensory cortex and entorhinal cortex; in the CA1 region of the hippocampus and in the motor cortex, no significant increase was observed when compared to the control group.

Based on co-drugs representing two different chemical entities and the co- and sequential administration of the two chemical entities, novel therapies for macular degeneration and TTR amyloidosis are provided. The first component (“Bispecific RBP4 / TTR ligand”) is a chemical entity that binds to both TTR and RBP4 in the RBP4 (retinol-binding protein 4)-TTR (transthyretin) complex, which participates in the delivery of retinol to the retina. This component reduces retinol transport from circulation to the retina and provides stabilization of the TTR tetramer. The second component (“C20-D3-visual chromophore-generating compound”) is a C20-D3 modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore, which is presented in the retina as C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at C20 reduces the formation of lipofuscin biretinol, but other functions (such as providing a precursor for the synthesis of the visual chromophore 11-cis-retinaldehyde in vivo) are not reduced.

An anti-aging traditional Chinese medicine composition and its preparation method belong to the field of traditional Chinese medicine technology. The composition consists of the following components by weight: 3-60 parts of Polygonatum sibiricum, 1-70 parts of Astragalus membranaceus, 2-40 parts of Lycium barbarum, and 1-40 parts of Ganoderma lucidum spore powder. The method is as follows: soak the raw materials except for Ganoderma lucidum spore powder; decoct the raw materials 1-3 times; combine the decoctions obtained after several decoctions and concentrate them to obtain concentrated decoction; prepare the concentrated decoction into freeze-dried powder; add Ganoderma lucidum spore powder to the freeze-dried powder and stir evenly. The pharmacodynamic research results of the anti-aging of the present invention are as follows: (1) The test drug can significantly prolong the average lifespan of naturally aging nematodes by 30%, which is better than Erjingwan and the Western medicine NMN; (2) improve exercise, feeding ability and nervous system function; (3) improve antioxidant capacity: reduce the fluorescence intensity of ROS and lipofuscin, and improve the survival rate of nematodes after H2O2 stress stimulation; (4) improve telomerase activity; (5) improve cognitive dysfunction and learning and memory ability.

Based on co-drugs representing two different chemical entities, and the co-administration and sequential administration of said two chemical entities, novel therapies are provided for macular degeneration, non-alcoholic fatty liver disease (NAFLD), and gouty arthritis (gout). The first component (“Selective RBP4 Antagonist”) is a chemical entity that interacts with RBP4 (retinol-binding protein 4), part of the RBP4-TTR (transthyretin) complex that delivers retinol to the retina. This component reduces the transport of retinol from circulation to the retina. The second component (“C20-D3-Visual Chromosome-Generating Compound”) is a C20-D3-modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore in the retina representing either C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at the C20 position reduces the formation of lipofuscin biretinol, while other functions (such as providing a precursor for the in vivo synthesis of visual chromophore 11-cis-retinaldehyde) are not reduced.

The present application relates to the technical field of biological medicine, in particular to a fresh product gynostemma pentaphyllum exosome and a preparation method and application thereof. The preparation method comprises the following steps: crushing the fresh product gynostemma pentaphyllum, adding a buffer solution to homogenate, filtering, and obtaining a primary extract; performing multi-stage differential centrifugation on the primary extract, removing impurities, and collecting supernatant; performing ultracentrifugation enrichment on the supernatant, collecting the precipitate and resuspending, and obtaining the fresh product gynostemma pentaphyllum exosome. The nematode experiment shows that the fresh product gynostemma pentaphyllum exosome can significantly prolong the lifespan of Caenorhabditis elegans, enhance the movement ability, reduce the accumulation of lipofuscin related to aging, and improve the heat stress survival rate. The fresh product gynostemma pentaphyllum exosome provided by the present application has clear components, good uniformity, and significant anti-aging activity, can provide material evidence for the scientific connotation of the "different use of raw and cooked" of gynostemma pentaphyllum, and be applied to the preparation of drugs for delaying aging, enhancing stress resistance, or preventing and treating neurodegenerative diseases, and has high scientific research value and clinical application prospect.